Literature DB >> 970369

Hemangiopericytoma-like intranasal tumors. A clinicopathologic study of 23 cases.

J Compagno, V J Hyams.   

Abstract

The clinical, microscopic, and gross pathologic features of 23 cases of intranasal hemangiopericytoma-like tumors are reviewed and studied. When in the nasal cavity, these lesions often originated in a paranasal sinus and extended into the nasal cavity secondarily. They occurred most commonly in adults in the sixth and seventh decades of life; there was no significant sex predilection. Twenty-two of the 23 patients were Caucasian. These patients most commonly had symptoms of nasal obstruction and epistaxis. Clinically the lesions were generally thought to represent allergic polyps. Although appearing microscopically as non-differentiated spindle-cell neoplasms, these lesions showed little nuclear or cytoplasmic pleomorphism, minimal mitotic activity, and no necrosis or hemorrhage or other evidence of anaplasia found in malignant tumors. Follow-up data showed no evidence to suggest a malignant or biologically unpredictable lesion. Nineteen of 22 cases followed showed no recurrence regardless of the treatment; those that recurred did so locally. No metastasis or other form of aggressive behavior attributed to hemangiopericytomas in other anatomic locations was seen in this series. Another case, diagnosed as a malignant hemangiopericytoma of the nasal cavity, showed dissimilar and anaplastic histologic features. This case metastasized and is discussed, though not included in this study.

Entities:  

Mesh:

Year:  1976        PMID: 970369     DOI: 10.1093/ajcp/66.4.672

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  18 in total

1.  Hemangiopericytoma of the nasal septum.

Authors:  M L Navarrete; J Maeso; M Pellicer
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

2.  β-catenin (CTNNB1) mutation and LEF1 expression in sinonasal glomangiopericytoma (sinonasal-type hemangiopericytoma).

Authors:  Yuka Suzuki; Shu Ichihara; Tomonori Kawasaki; Hiroyuki Yanai; Satoshi Kitagawa; Yoshie Shimoyama; Shigeo Nakamura; Masato Nakaguro
Journal:  Virchows Arch       Date:  2018-05-07       Impact factor: 4.064

Review 3.  Pitfalls in the histopathologic diagnosis of pyogenic granuloma.

Authors:  S B Kapadia; D K Heffner
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

4.  D2-40 staining in sinonasal-type hemangiopericytoma--further evidence of distinction from conventional hemangiopericytoma and solitary fibrous tumor.

Authors:  Torsten Hansen; Kathrin Katenkamp; Detlef Katenkamp
Journal:  Virchows Arch       Date:  2005-12-16       Impact factor: 4.064

5.  Sinonasal hemangiopericytoma: case report and literature review.

Authors:  J K Thiringer; P D Costantino; G Houston
Journal:  Skull Base Surg       Date:  1995

6.  Striking pathology gold: a singular experience with daily reverberations: sinonasal hemangiopericytoma (glomangiopericytoma) and oncogenic osteomalacia.

Authors:  Margaret Brandwein-Gensler; Gene P Siegal
Journal:  Head Neck Pathol       Date:  2012-03-20

Review 7.  Craniofacial hemangiopericytoma associated with oncogenic osteomalacia: case report.

Authors:  F A Sandhu; R L Martuza
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

8.  [Sinunasal hemangiopericytoma].

Authors:  M Neudert; M Haase; D El-Hifnawi; T Beleites; T Zahnert
Journal:  HNO       Date:  2010-10       Impact factor: 1.284

9.  Nuclear expression and gain-of-function β-catenin mutation in glomangiopericytoma (sinonasal-type hemangiopericytoma): insight into pathogenesis and a diagnostic marker.

Authors:  Jerzy Lasota; Anna Felisiak-Golabek; F Zahra Aly; Zeng-Feng Wang; Lester D R Thompson; Markku Miettinen
Journal:  Mod Pathol       Date:  2014-11-28       Impact factor: 7.842

10.  [Solitary fibrous tumor and haemangiopericytoma: what is new?].

Authors:  T Knösel; B Schulz; K Katenkamp; D Katenkamp; I Petersen
Journal:  Pathologe       Date:  2010-03       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.